BioCryst Pharmaceuticals, Inc. Share Price
Stocks
BCRX
US09058V1035
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 08/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 8.400 USD | +5.66% |
|
+0.84% | +7.69% |
| 05/10 | Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board | CI |
| 05/10 | BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves | MT |
| Market Cap | 214.65Cr 191.79Cr 178.93Cr 162.53Cr 306.1Cr 21TCr 308.39Cr 2.15TCr 840.05Cr 11TCr 805.84Cr 788.41Cr 34TCr | P/E 2026 * |
-3.64x | P/E 2027 * | 12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 226.44Cr 202.32Cr 188.76Cr 171.46Cr 322.92Cr 22TCr 325.33Cr 2.27TCr 886.2Cr 11TCr 850.1Cr 831.72Cr 36TCr | EV / Sales 2026 * |
3.19x | EV / Sales 2027 * | 2.76x |
| Free-Float |
94.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| BCRX | Delayed | |
CBOE
| BCRX | Real-time | |
|
Boerse Muenchen
| BO1 | Real-time | |
|
Mexican S.E.
| BCRX * | End-of-day quote | |
|
Tradegate
| BO1 | Real-time | |
|
Deutsche Boerse AG
| BO1 | Delayed | |
|
Börse Stuttgart
| BO1 | Delayed | |
|
Berne S.E.
| BO1 | End-of-day quote |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | +5.66% | ||
| 1 week | +0.84% | ||
| Current month | +0.84% | ||
| 1 month | -15.66% | ||
| 3 months | -23.57% | ||
| 6 months | -12.41% | ||
| Current year | +7.69% |
| 1 week | 7.86 |  | 8.42 |
| 1 month | 7.86 | | 9.23 |
| Current year | 6.23 | | 11.22 |
| 1 year | 6 | | 11.22 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 01/01/2026 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 07/07/2025 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 06/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
BRD | Director/Board Member | 65 | 01/01/2007 |
Theresa Heggie
BRD | Director/Board Member | 64 | 03/12/2018 |
Charles Gayer
BRD | Director/Board Member | 55 | 01/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Free | Director | 644 | 0.0003% | ||
| 31/08/26 | Free | Director | 644 | 0.0003% | ||
| 31/08/26 | Free | Director | 1,288 | 0.0005% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +5.66% | +0.84% | +20.86% | +32.91% | 214.65Cr | |
| +4.16% | +4.16% | +49.37% | +94.17% | 7.47TCr | |
| -16.38% | -16.68% | +2.04% | +50.15% | 5.87TCr | |
| -1.92% | +1.07% | +4.00% | +32.07% | 4.84TCr | |
| +0.50% | -2.14% | +331.33% | +702.20% | 4.31TCr | |
| -0.72% | -3.99% | +28.50% | +29.94% | 4.25TCr | |
| +0.34% | -0.52% | +6.56% | +109.35% | 4.14TCr | |
| -0.11% | +1.96% | +9.19% | +52.66% | 3.13TCr | |
| -0.50% | -3.10% | -10.19% | -14.35% | 2.39TCr | |
| -3.32% | -10.86% | -37.32% | +316.28% | 2.22TCr | |
| Average | -1.23% | -2.35% | +40.43% | +140.54% | 3.88TCr | |
| Weighted average by Cap. | -2.10% | -1.58% | +48.96% | +144.14% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 71Cr 63Cr 59Cr 54Cr 101.26Cr 6.87TCr 102.02Cr 711.32Cr 277.9Cr 3.49TCr 266.58Cr 260.81Cr 11TCr | 74Cr 66Cr 62Cr 56Cr 105.34Cr 7.15TCr 106.12Cr 739.94Cr 289.08Cr 3.63TCr 277.31Cr 271.31Cr 12TCr |
| Net income | -58Cr -52Cr -49Cr -44Cr -83Cr -5.63TCr -84Cr -583.23Cr -227.86Cr -2.86TCr -218.58Cr -213.85Cr -9.21TCr | 18Cr 16Cr 15Cr 14Cr 26Cr 1.75TCr 26Cr 181.61Cr 71Cr 891.9Cr 68Cr 67Cr 2.87TCr |
| Net Debt | 12Cr 11Cr 9.83Cr 8.93Cr 17Cr 1.14TCr 17Cr 118.12Cr 46Cr 580.1Cr 44Cr 43Cr 1.86TCr | -11Cr -9.69Cr -9.04Cr -8.22Cr -15Cr -1.05TCr -16Cr -108.69Cr -42Cr -533.8Cr -41Cr -40Cr -1.72TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/26/07 | $8.400 | +5.66% | 51,22,732 |
| 06/26/06 | $7.950 | -1.85% | 39,44,024 |
| 05/26/05 | $8.100 | -0.86% | 47,12,254 |
| 02/26/02 | $8.170 | +0.62% | 61,48,675 |
| 01/26/01 | $8.120 | -2.52% | 68,69,722 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
